Changes in serum tumor markers in type 2 diabetes mellitus with microalbuminuria
- PMID: 38130399
- PMCID: PMC10733510
- DOI: 10.3389/fendo.2023.1247099
Changes in serum tumor markers in type 2 diabetes mellitus with microalbuminuria
Abstract
Objectives: The objective of this study was to investigate changes in serum tumor markers in type 2 diabetes mellitus (T2DM) with microalbuminuria and analyze the relationship between tumor markers and microalbuminuria.
Methods: A total of 956 T2DM patients aged 40-70 years hospitalized in the Department of Endocrinology, Xinhua Hospital, China, affiliated with Shanghai Jiaotong University School of Medicine, were enrolled from January 2018 to December 2020. The sample comprised 313 T2DM patients with microalbuminuria and 643 T2DM patients with normal urinary microalbumin levels. After assessing the changes in serum tumor markers in T2DM with microalbuminuria, we analyzed the risk of microalbuminuria by the serum tumor marker category using multiple logistic regression analysis.
Results: Serum CEA, CA199, CA125, CA153, CA211, SCC, CA242, and CA50 levels were significantly higher in T2DM patients with microalbuminuria than in those without microalbuminuria, while serum AFP levels were lower in the microalbuminuria group (P < 0.05). Following adjustment of confounders, serum CEA, CA211, and SCC were independently associated with microalbuminuria in T2DM. An ROC curve was used to estimate the cutoff point of tumor markers for microalbuminuria. Taking the values under the cutoff points as a reference, values for CEA, CA211, and SCC above the cutoff points indicated a significantly high risk of microalbuminuria. The OR of increased CEA for microalbuminuria was 2.006 (95%CI 1.456-2.765), the OR of increased CA211 for microalbuminuria was 1.505 (95%CI 1.092-2.074), and the OR of increased SCC for microalbuminuria was 1.958 (95%CI 1.407-2.724).
Conclusion: Several serum tumor markers were related to microalbuminuria in T2DM. Serum tumor markers such as CEA, SCC, and CA211 may indicate early diabetic nephropathy, particularly when elevated in combination.
Keywords: UACR; diabetes mellitus; microalbuminuria; tumor markers; type 2.
Copyright © 2023 Chen, Du, Li, Su, Zhang and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Serum tumor markers expression (CA199, CA242, and CEA) and its clinical implications in type 2 diabetes mellitus.World J Diabetes. 2024 Feb 15;15(2):232-239. doi: 10.4239/wjd.v15.i2.232. World J Diabetes. 2024. PMID: 38464372 Free PMC article.
-
Correlation between tumor markers and type 2 diabetes mellitus complications and their related influencing factors.Ann Palliat Med. 2022 Jan;11(1):58-67. doi: 10.21037/apm-21-3429. Ann Palliat Med. 2022. PMID: 35144398
-
Mir-421 in plasma as a potential diagnostic biomarker for precancerous gastric lesions and early gastric cancer.PeerJ. 2019 Jun 17;7:e7002. doi: 10.7717/peerj.7002. eCollection 2019. PeerJ. 2019. PMID: 31245174 Free PMC article.
-
Association Between Serum Irisin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis.Horm Metab Res. 2021 May;53(5):293-300. doi: 10.1055/a-1475-4444. Epub 2021 May 7. Horm Metab Res. 2021. PMID: 33962476 Review.
-
Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.World J Gastroenterol. 2014 Apr 14;20(14):4085-92. doi: 10.3748/wjg.v20.i14.4085. World J Gastroenterol. 2014. PMID: 24744600 Free PMC article. Review.
Cited by
-
HMOX1 as a Novel Biomarker for Glucose-Lipid Metabolism Disorder and T2DM: Systematic Bioinformatics Investigation and Experimental Verification.ACS Omega. 2025 Apr 16;10(16):16123-16137. doi: 10.1021/acsomega.4c09662. eCollection 2025 Apr 29. ACS Omega. 2025. PMID: 40321502 Free PMC article.
-
Association between serum tumor markers and diabetic nephropathy in type 2 diabetes patients: a cross-sectional survey in Western China.BMC Endocr Disord. 2025 Jul 1;25(1):150. doi: 10.1186/s12902-025-01932-1. BMC Endocr Disord. 2025. PMID: 40598128 Free PMC article.
-
Integrative proteomic analysis reveals the potential diagnostic marker and drug target for the Type-2 diabetes mellitus.J Diabetes Metab Disord. 2025 Jan 22;24(1):55. doi: 10.1007/s40200-025-01562-3. eCollection 2025 Jun. J Diabetes Metab Disord. 2025. PMID: 39850446 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous